Cytori Therapeutics Inc (NASDAQ:CYTX)’s share price dropped 7.5% on Friday . The stock traded as low as $0.24 and last traded at $0.24. Approximately 582,010 shares changed hands during trading, an increase of 2% from the average daily volume of 572,150 shares. The stock had previously closed at $0.26.

CYTX has been the subject of several recent research reports. Zacks Investment Research raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. Maxim Group reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Monday, December 3rd.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Barclays PLC increased its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 724.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 99,747 shares of the biotechnology company’s stock after purchasing an additional 87,647 shares during the period. Barclays PLC owned 0.76% of Cytori Therapeutics worth $29,000 as of its most recent SEC filing. 3.10% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Cytori Therapeutics (CYTX) Stock Price Down 7.5%” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2019/03/24/cytori-therapeutics-cytx-stock-price-down-7-5.html.

About Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

Featured Article: Earnings Per Share

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.